NewsResearch
CheckMate 9LA: What the Lung Cancer Trial Found
CheckMate 9LA tested two immune drugs plus a deliberately short course of chemotherapy — two cycles, not four — as first treatment for advanced non-small-cell lung cancer. People lived longer, at a cost in side effects.
Original commentary from the Cancer Explained editorial team.
Please note: this page is educational only — it is not medical advice, and it does not speculate about anyone’s health beyond reliable public reporting. For questions about your own health, talk with your healthcare team.
Two cycles of chemotherapy, not four
Two immune drugs together — nivolumab and ipilimumab — already worked in advanced lung cancer without any chemotherapy. But they can be slow, and some people's cancer grows too fast to wait.
CheckMate 9LA tried a compromise. Give the two immune drugs, and add just enough chemotherapy to hold the line early on. Two cycles, where the standard course is four. The comparison group got the standard four cycles of chemotherapy and no immune drugs.
How the two groups were treated
1,150 people were enrolled at 103 hospitals in 19 countries. 719 were randomised, half to each group: 361 to the combination and 358 to chemotherapy alone.
Everyone had stage IV or recurrent non-small-cell lung cancer and had not been treated for it before. All were well enough to look after themselves day to day. The combination arm got nivolumab every three weeks, ipilimumab every six weeks, and two cycles of platinum-based chemotherapy chosen to suit the tumour type. Nobody was blinded.
What the interim analysis found
| Field | Detail |
|---|---|
| Trial | CheckMate 9LA |
| Identifier | NCT03215706 |
| Phase | Phase 3 |
| Design | Randomised, open-label |
| Cancer type | Stage IV or recurrent non-small-cell lung cancer, untreated |
| Comparator | Nivolumab, ipilimumab and two chemotherapy cycles, against four cycles of chemotherapy |
| Primary endpoint | Overall survival |
The trial hit its target at a planned interim look, after a median of 9.7 months of follow-up. Median survival was 14.1 months (95% CI 13.2 to 16.2) with the combination and 10.7 months (95% CI 9.5 to 12.4) with chemotherapy alone. The hazard ratio was 0.69 (96.71% CI 0.55 to 0.87; p=0.00065).
What the extra three months of follow-up added
The researchers also reported an exploratory look with a median of 13.2 months of follow-up. Median survival was then 15.6 months (95% CI 13.9 to 20.0) against 10.9 months (95% CI 9.5 to 12.6), hazard ratio 0.66 (95% CI 0.55 to 0.80).
The gap widened rather than shrank. That said, a follow-up of just over a year is short for a survival claim, and the report cannot say what the curves do at three or five years.
The cost in side effects
Serious treatment-related side effects of any grade occurred in 106 people on the combination (30%) and 62 on chemotherapy alone (18%).
The pattern of severe events differed as well. Anaemia was far more common with chemotherapy alone (14% against 6%). Diarrhoea and raised lipase — a pancreas enzyme — were more common with the combination (4% against 1%, and 6% against 1%). Seven people in the combination group (2%) and six in the chemotherapy group (2%) died of causes the investigators put down to treatment.
What this trial cannot tell you
- Whether this beats the more common option. There was no arm giving chemotherapy plus a single immune drug, which is what many people are actually offered. This trial cannot rank the two.
- What happens long-term. The primary analysis ran to a median of 9.7 months.
- Who benefits most. Randomisation was stratified by tumour type, sex and PD-L1 level, but the report does not identify a group that should choose this over the alternatives.
- How it feels in practice. Four drugs mean more infusions, more monitoring, and more ways for something to go wrong.
Questions about a first lung cancer treatment
- How many different drugs would this plan involve, and over how long?
- Is there a reason to add the second immune drug in my case?
- Which side effects would mean stopping, rather than pausing?
Sources
This article was written from the sources below, which were checked on the source-check date shown above.
How this article was prepared
Prepared by Cancer Explained's AI-assisted editorial system and checked against the sources listed below. This article has not been reviewed by a healthcare professional unless a named reviewer is specifically shown.
Cancer Explained is published by the National Cancer Information Foundation as a nonprofit-oriented public-interest education project. It is not a diagnostic service, does not recommend treatments, and is not for emergencies.
Found an error, a broken source link, outdated information, or wording that feels insensitive? Report it here — we log and act on material corrections.
Know someone who needs this?
Plenty of people are looking for something like this and do not know where to start. If this would help a friend or someone you love, send it on — we have written an opening line so you do not have to stare at an empty message. You can change every word of it.
Your message is written and sent in your own email or messaging app — we never see who you send it to, and nothing is added to any list.
Put the story in context
Prevention, possible warning signs, screening, and diagnosis
This story relates to Lung cancer. The information below is general: it does not reveal anything else about a public person’s health, and not every point applies to every cancer. Personal advice depends on age, symptoms, family history, exposures, and medical history.
Prevention and risk reduction
Not every cancer can be prevented. Avoiding tobacco, protecting skin from ultraviolet radiation, limiting alcohol, staying active, and receiving recommended HPV or hepatitis B vaccination can lower the risk of certain cancers. A risk factor is not a prediction or a cause in one individual.
Symptoms and possible early signs
Possible signs vary and are often caused by conditions other than cancer. Changes worth discussing include a new lump, unexplained bleeding or weight loss, a persistent cough, lasting bowel or bladder changes, a changing skin spot, or symptoms that persist or worsen. Some early cancers cause no symptoms.
Screening and early detection
Screening looks for certain cancers before symptoms begin. Recommended tests exist only for some cancers and depend on age and risk. Screening can have benefits and harms; it is not the same as evaluating a new symptom, and there is no single routine scan or blood test that reliably screens for every cancer.
How cancer is diagnosed
Diagnosis may involve a history and exam, imaging, laboratory tests, and often a biopsy. Pathology can identify the cancer type and may test biomarkers that guide treatment. Symptoms, screening results, tumor markers, or online stories alone cannot confirm cancer.
Learn about this story’s cancer topic
A public story may encourage questions, but it should not be used to estimate your risk or choose testing. Contact a healthcare professional about a persistent or concerning change. Seek urgent care for severe or rapidly worsening symptoms.